An interesting Outlook from June 2017 by Evaluate Group. As the development of the drug market is important for the excipient market it can give also some indication some good indication where we will move to.

“The tenth edition of EvaluatePharma’s World Preview brings together many of our analyses to provide a top level insight, from the world’s  financial markets, into the expected performance of the industry between now and 2022. Based on EvaluatePharma’s coverage of the world’s leading 6,500 pharmaceutical and biotech companies, the World Preview highlights trends in prescription drug sales, patent risk, R&D spend, global brand sales and market performance by therapy area. Also included this year are analysis on Worldwide Pharma Innovation 2008-2022 with insights into pipeline value creation through 2022, fastest growing companies and the top performers in terms of RoI.”